💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Duloxetine

CHEMBL1175 Phase 4 अनुमोदित Small molecule
Half-Life
12 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
297.4 g/mol
LogP
4.3
Phase
4

Raising the availability of two neurotransmitters at once, duloxetine inhibits the reuptake of both serotonin and norepinephrine, placing it in the serotonin-norepinephrine reuptake inhibitor class. The dual action supports mood while also engaging pain-modulating pathways in the nervous system, which is why the drug treats not only depression and anxiety but also chronic nerve pain and fibromyalgia. A small molecule (C18H19NOS) with a half-life of about 12 hours, it is generally dosed once or twice daily. Its effect on descending pain pathways distinguishes it from antidepressants that act on serotonin alone and underlies its use in painful physical conditions. Duloxetine is an approved medicine bridging psychiatric and pain-related indications.

A serotonin-norepinephrine reuptake inhibitor (SNRI) used to treat depression, anxiety, nerve pain, and fibromyalgia. It works by increasing the availability of serotonin and norepinephrine in the brain.

आणविक भार

297.4150 g/mol

LogP

4.30

TPSA

49.50 Ų

लिपिंस्की RO5

उत्तीर्ण

चिकित्सीय क्षेत्र

अनिद्रा अल्ज़ाइमर रोग इंफ्लेमेटरी बाउल डिज़ीज़ ऑन्कोलॉजी ऑप्थल्मोलॉजी (नेत्र विज्ञान) कोलोरेक्टल कैंसर क्रॉनिक ऑब्सट्रक्टिव पल्मोनरी डिज़ीज़ (COPD) क्रॉनिक किडनी डिज़ीज़ गैस्ट्रोइसोफेजियल रिफ्लक्स रोग जनरलाइज़्ड एंग्ज़ाइटी डिसऑर्डर टाइप 2 मधुमेह दर्द प्रबंधन दीर्घकालिक दर्द नॉन-अल्कोहलिक फैटी लिवर डिज़ीज़ पार्किंसन रोग प्रोस्टेट कैंसर बाइपोलर डिसऑर्डर मल्टीपल स्क्लेरोसिस माइग्रेन मिर्गी (एपिलेप्सी) मेजर डिप्रेसिव डिसऑर्डर श्वसन रोग संक्रामक रोग सिज़ोफ्रेनिया सिस्टेमिक ल्यूपस एरिथेमेटोसस स्ट्रोक स्तन कैंसर हृदय-संवहनी रोग

दवा वर्ग

N — N - तंत्रिका तंत्र

क्रिया का तंत्र

Serotonin-norepinephrine reuptake inhibitor (SNRI).

Pharmacokinetics (PK)

Half-Life 12 hours

Pharmacodynamics (PD)

तंत्र

Serotonin-norepinephrine reuptake inhibitor (SNRI).

2D संरचना

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1

                

                

                
                

                    
InChI

                    
InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C18H19NOS

                    

                    
                    

                        
HBD / HBA

                        
1 / 3

                    

                    
                    

                        
घूर्णनीय बंधन

                        
6

                    

                    
                    
                    

                        
भारी परमाणु

                        
21

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            SLC6A4 (सेरोटोनिन ट्रांसपोर्टर)
                            Inhibitor
                        

                        
                        Primary Target
                        
                    

                    
                    

                        

                            CYP2D6 (साइटोक्रोम P450 2D6 (CYP2D6))
                            Inhibitor
                        

                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Major


                            
                                Duloxetine + Tramadol
                            
                        

                        
                        
Duloxetine, a serotonin-norepinephrine reuptake inhibitor, combined with tramadol markedly elevates the risk of serotonin syndrome.

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Duloxetine + Fluoxetine
                            
                        

                        
                        
Fluoxetine is a potent CYP2D6 inhibitor that substantially increases duloxetine plasma levels, while both agents also increase serotonin syndrome risk.

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Duloxetine + Sertraline
                            
                        

                        
                        
Combining duloxetine and sertraline, two serotonergic antidepressants, markedly increases the risk of serotonin syndrome without added efficacy.

                        
                    
                    
                    
                        

                            

  
  Minor


                            
                                Duloxetine + Pregabalin
                            
                        

                        
                        
Duloxetine and pregabalin are commonly co-prescribed for neuropathic pain with complementary mechanisms; additive CNS effects including dizziness, somnolence, and cognitive impairment can occur.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Duloxetine + Sumatriptan
                            
                        

                        
                        
Duloxetine and sumatriptan co-administration carries a serotonin syndrome risk due to complementary mechanisms of serotonergic stimulation.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Duloxetine + Carbamazepine
                            
                        

                        
                        
Carbamazepine substantially reduces duloxetine plasma levels through CYP1A2 and CYP3A4 induction, risking loss of antidepressant efficacy.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
अक्सर पूछे जाने वाले प्रश्न

                

                    
                    

                        
                        

                            
A serotonin-norepinephrine reuptake inhibitor (SNRI) used to treat depression, anxiety, nerve pain, and fibromyalgia. It works by increasing the availability of serotonin and norepinephrine in the brain.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Serotonin-norepinephrine reuptake inhibitor (SNRI).

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Duloxetine: Half-life: 12 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Duloxetine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Acetaminophen
                            Small molecule
                        
                        
                        
                            Aspirin
                            Small molecule
                        
                        
                        
                            Sertraline
                            Small molecule
                        
                        
                        
                            Escitalopram
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1175.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 60835.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
चिकित्सा अस्वीकरण

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.